

ERRATUM

Correction to: Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

Jutel, M, Agache, I, Zemelka-Wiacek, M, et al. Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper. *Allergy*. 2023;78:2851-2874. doi:10.1111/all.15889

In the article, there was a missing paragraph from section 2.4.4 *Other possible types of type IV hypersensitivity* and the text below should have been added.

2.4.4 Other possible types of type IV hypersensitivity

The p-i concept (=pharmacological interaction with immune receptors) postulates that some drugs can bind directly and reversibly (non-covalently) to immune receptors and thereby stimulate the cells. A certain drug may bind to a particular T-cell receptor (TCR) or bind directly to a certain HLA-molecule, which would explain the striking HLA associations of some drug hypersensitivity reactions. This drug binding suffices—together with TCR interactions with the HLA—to stimulate the T cell to secrete cytokines, increase and exert cytotoxicity.¹⁰⁸

In References, the sequence and citations of references # 55 to 165 were incorrect and have been renumbered throughout the article and references. The correct list of references is listed below.

REFERENCES

55. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. *J Allergy Clin Immunol*. 2010;125(2 Suppl 2):S73-S80. doi:10.1016/j.jaci.2009.11.017
56. Bellinghausen I, Khatri R, Saloga J. Current strategies to modulate regulatory T cell activity in allergic inflammation. *Front Immunol*. 2022;13:912529. doi:10.3389/fimmu.2022.912529
57. Qin L, Tang LF, Cheng L, Wang HY. The clinical significance of allergen-specific IgG4 in allergic diseases. *Front Immunol*. 2022;13:1032909. doi:10.3389/fimmu.2022.1032909
58. Pilette C, Nouri-Aria KT, Jacobson MR, et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. *J Immunol*. 2007;178(7):4658-4666. doi:10.4049/jimmunol.178.7.4658
59. Gigon L, Fettelet T, Yousefi S, Simon D, Simon HU. Eosinophils from a to Z. *Allergy*. 2023;78(7):1810-1846. doi:10.1111/all.15751
60. Lee E, Kim M, Jeon K, et al. Mean platelet volume, platelet distribution width, and platelet count, in connection with immune thrombocytopenic purpura and essential thrombocytopenia. *Lab Med*. 2019;50(3):279-285. doi:10.1093/labmed/lmy082
61. Li TX, Sun FT, Ji BJ. Correlation of IgG subclass with blood cell parameters in patients with autoimmune hemolytic anemia. *Zhongguo Shi Yan Xue Ye Xue Za Zhi*. 2019;27(1):197-201. doi:10.7534/j.issn.1009-2137.2019.01.032
62. Leonard A, Hittson Boal L, Pary P, et al. Identification of red blood cell antibodies in maternal breast milk implicated in prolonged hemolytic disease of the fetus and newborn. *Transfusion*. 2019;59(4):1183-1189. doi:10.1111/trf.15154
63. Vries TB, Boerma S, Doornebal J, Dikkeschei B, Stegeman C, Veneman TF. Goodpasture's syndrome with negative anti-glomerular basement membrane antibodies. *Eur J Case Rep Intern Med*. 2017;4(8):000687. doi:10.12890/2017_000687
64. Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. *Front Immunol*. 2015;6:368. doi:10.3389/fimmu.2015.00368
65. Sauler M, Bazan IS, Lee PJ. Cell death in the lung:the apoptosis-necroptosis Axis. *Annu Rev Physiol*. 2019;81:375-402. doi:10.1146/annurev-physiol-020518-114320

66. Dai W, Cheng J, Leng X, Hu X, Ao Y. The potential role of necroptosis in clinical diseases (review). *Int J Mol Med*. 2021;47(5):89. doi:10.3892/ijmm.2021.4922
67. Bajwa SF, Mohammed RH. Type II hypersensitivity reaction. StatPearls [Internet]. StatPearls Publishing;2023.
68. Usman N, Annamaraju P. Type III hypersensitivity reaction. StatPearls [Internet]. StatPearls Publishing;2022.
69. Ramos BF, Zhang Y, Jakschik BA. Neutrophil elicitation in the reverse passive Arthus reaction. Complement-dependent and -independent mast cell involvement. *J Immunol*. 1994;152(3):1380-1384.
70. Sylvestre DL, Ravetch JV. A dominant role for mast cell fc receptors in the Arthus reaction. *Immunity*. 1996;5(4):387-390. doi:10.1016/s1074-7613(00)80264-2
71. Sylvestre DL, Ravetch JV. Fc receptors initiate the Arthus reaction:redefining the inflammatory cascade. *Science*. 1994;265(5175):1095-1098. doi:10.1126/science.8066448
72. Krystal-Whittemore M, Dileepan KN, Wood JG. Mast cell:a multi-functional master cell. *Front Immunol*. 2016;6:620. doi:10.3389/fimmu.2015.00620
73. Shushakova N, Skokowa J, Schulman J, et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcγR3s in immune complex-induced lung disease. *J Clin Invest*. 2002;110(12):1823-1830. doi:10.1172/JCI16577
74. Romano A, Valluzzi RL, Caruso C, Maggioletti M, Gaeta F. Non-immediate cutaneous reactions to Beta-lactams:approach to diagnosis. *Curr Allergy Asthma Rep*. 2017;17(4):23. doi:10.1007/s11882-017-0691-4
75. Pan J, Zhang M, Wang J, et al. Interferon-gamma is an autocrine mediator for dendritic cell maturation. *Immunol Lett*. 2004;94(1-2):141-151. doi:10.1016/j.imlet.2004.05.003
76. McLaughlin TA, Khayumbi J, Ongalo J, et al. CD4 T cells in Mycobacterium tuberculosis and Schistosoma mansoni Co-infected individuals maintain functional TH1 responses. *Front Immunol*. 2020;11:127. doi:10.3389/fimmu.2020.00127
77. Seillet C, Belz GT, Huntington ND. Development, homeostasis, and heterogeneity of NK cells and ILC1. *Curr Top Microbiol Immunol*. 2016;395:37-61. doi:10.1007/82_2015_474
78. Trautmann A, Akdis M, Kleemann D, et al. T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. *J Clin Invest*. 2000;106(1):25-35. doi:10.1172/JCI9199
79. Trautmann A, Schmid-Grendelmeier P, Krüger K, et al. T cells and eosinophils cooperate in the induction of bronchial epithelial cell apoptosis in asthma. *J Allergy Clin Immunol*. 2002;109(2):329-337. doi:10.1067/mai.2002.121460
80. Preglej T, Hamminger P, Luu M, et al. Histone deacetylases 1 and 2 restrain CD4+ cytotoxic T lymphocyte differentiation. *JCI Insight*. 2020;5(4):e133393. doi:10.1172/jci.insight.133393
81. Bhat P, Leggat G, Waterhouse N, Frazer IH. Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. *Cell Death Dis*. 2017;8(6):e2836. doi:10.1038/cddis.2017.67
82. Valkenburg SA, Gras S, Guillonneau C, et al. Protective efficacy of cross-reactive CD8+ T cells recognising mutant viral epitopes depends on peptide-MHC-I structural interactions and T cell activation threshold. *PLoS Pathog*. 2010;6(8):e1001039. doi:10.1371/journal.ppat.1001039
83. Zimmermann M, Koreck A, Meyer N, et al. TNF-like weak inducer of apoptosis (TWEAK) and TNF-α cooperate in the induction of keratinocyte apoptosis. *J Allergy Clin Immunol*. 2011;127(1):200-207. doi:10.1016/j.jaci.2010.11.005
84. Rebane A, Zimmermann M, Aab A, et al. Mechanisms of IFN-γ-induced apoptosis of human skin keratinocytes in patients with atopic dermatitis. *J Allergy Clin Immunol*. 2012;129(5):1297-1306. doi:10.1016/j.jaci.2012.02.020
85. Valente M, Dölen Y, van Dinther E, et al. Cross-talk between iNKT cells and CD8 T cells in the spleen requires the IL-4/CCL17 axis for the generation of short-lived effector cells. *Proc Natl Acad Sci U S A*. 2019;116(51):25816-25827. doi:10.1073/pnas.1913491116
86. Eguiluz-Gracia I, Layhadi JA, Rondon C, Shamji MH. Mucosal IgE immune responses in respiratory diseases. *A-Curr Opin Pharmacol*. 2019;46:100-107. doi:10.1016/j.coph.2019.05.009
87. Fahy JV. Type 2 inflammation in asthma—Present in most, absent in many. *Nat Rev Immunol*. 2015;15(1):57-65. doi:10.1038/nri3786
88. Datsi A, Steinhoff M, Ahmad F, Alam M, Buddenkotte J. Interleukin-31: the “itchy” cytokine in inflammation and therapy. *Allergy*. 2021;76(10):2982-2997. doi:10.1111/all.14791
89. Garcovich S, Maurelli M, Gisondi P, Peris K, Yosipovitch G, Girolomoni G. Pruritus as a distinctive feature of type 2 inflammation. *Vaccines (Basel)*. 2021;9(3):303. doi:10.3390/vaccines9030303
90. Abdelaziz MH, Wang H, Cheng J, Xu H. Th2 cells as an intermediate for the differentiation of naïve T cells into Th9 cells, associated with the Smad3/Smad4 and IRF4 pathway. *Exp Ther Med*. 2020;19(3):1947-1954. doi:10.3892/etm.2020.8420
91. Kaplan MH, Hufford MM, Olson MR. The development and in vivo function of T helper 9 cells. *Nat Rev Immunol*. 2015;15(5):295-307. doi:10.1038/nri3824
92. Starkey MR, McKenzie AN, Belz GT, Hansbro PM. Pulmonary group 2 innate lymphoid cells: surprises and challenges. *Mucosal Immunol*. 2019;12(2):299-311. doi:10.1038/s41385-018-0130-4

93. Orimo K, Tamari M, Saito H, Matsumoto K, Nakae S, Morita H. Characteristics of tissue-resident ILCs and their potential as therapeutic targets in mucosal and skin inflammatory diseases. *Allergy*. 2021;76(11):3332-3348. doi:10.1111/all.14863
94. Wawrzyniak P, Wawrzyniak M, Wanke K, et al. Regulation of bronchial epithelial barrier integrity by type 2 cytokines and histone deacetylases in asthmatic patients. *J Allergy Clin Immunol*. 2017;139(1):93-103. doi:10.1016/j.jaci.2016.03.050
95. Sugita K, Steer CA, Martinez-Gonzalez I, et al. Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients. *J Allergy Clin Immunol*. 2018;141(1):300-310.e11. doi:10.1016/j.jaci.2017.02.038
96. Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. *Cytokine*. 2015;75(1):14-24. doi:10.1016/j.cyto.2015.05.010
97. Miyake K, Shibata S, Yoshikawa S, Karasuyama H. Basophils and their effector molecules in allergic disorders. *Allergy*. 2021;76(6):1693-1706. doi:10.1111/all.14662
98. Akdis M, Aab A, Altunbulakli C, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β , and TNF- α : receptors, functions, and roles in diseases. *J Allergy Clin Immunol*. 2016;138(4):984-1010. doi:10.1016/j.jaci.2016.06.033
99. Hancock A, Armstrong L, Gama R, Millar A. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. *Am J Respir Cell Mol Biol*. 1998;18(1):60-65. doi:10.1165/ajrcmb.18.1.2627
100. Bochner BS. Systemic activation of basophils and eosinophils: markers and consequences. *J Allergy Clin Immunol*. 2000;106(5 Suppl):S292-S302. doi:10.1067/mai.2000.110164
101. Valent P, Klion AD, Roufosse F, et al. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. *Allergy*. 2023;78(1):47-59. doi:10.1111/all.15544
102. Thompson-Souza GA, Vasconcelos CRI, Neves JS. Eosinophils: focus on DNA extracellular traps. *Life Sci*. 2022;311(Pt B):121191. doi:10.1016/j.lfs.2022.121191
103. Johnson MO, Wolf MM, Madden MZ, et al. Distinct regulation of Th17 and Th1 cell differentiation by Glutaminase-dependent metabolism. *Cell*. 2018;175(7):1780-1795.e19. doi:10.1016/j.cell.2018.10.001
104. Mills KHG. IL-17 and IL-17-producing cells in protection versus pathology. *Nat Rev Immunol*. 2023;23(1):38-54. doi:10.1038/s41577-022-00746-9
105. Tamassia N, Arruda-Silva F, Wright HL, et al. Human neutrophils activated via TLR8 promote Th17 polarization through IL-23. *J Leukoc Biol*. 2019;105(6):1155-1165. doi:10.1002/JLB.MA0818-308R
106. Keir HR, Chalmers JD. Neutrophil extracellular traps in chronic lung disease: implications for pathogenesis and therapy. *Eur Respir Rev*. 2022;31(163):210241. doi:10.1183/16000617.0241-2021
107. Croxatto D, Micheletti A, Montaldo E, et al. Group 3 innate lymphoid cells regulate neutrophil migration and function in human decidua. *Mucosal Immunol*. 2016;9(6):1372-1383. doi:10.1038/mi.2016.10
108. Pichler WJ, Hausmann O. Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms. *Int Arch Allergy Immunol*. 2016;171(3-4):166-179. doi:10.1159/000453265
109. Czarnowicki T, Gonzalez J, Shemer A, et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. *J Allergy Clin Immunol*. 2015;136(1):104-115.e7. doi:10.1016/j.jaci.2015.01.020
110. Jones CP, Gregory LG, Causton B, Campbell GA, Lloyd CM. Activin a and TGF- β promote T(H)9 cell-mediated pulmonary allergic pathology. *J Allergy Clin Immunol*. 2012;129(4):1000-10.e3. doi:10.1016/j.jaci.2011.12.965
111. Lu LF, Lind EF, Gondek DC, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. *Nature*. 2006;442(7106):997-1002. doi:10.1038/nature05010
112. Licona-Limón P, Henao-Mejia J, Temann AU, et al. Th9 cells drive host immunity against gastrointestinal Worm infection. *Immunity*. 2013;39(4):744-757. doi:10.1016/j.immuni.2013.07.020
113. Xiao X, Balasubramanian S, Liu W, et al. OX40 signaling favors the induction of T(H)9 cells and airway inflammation. *Nat Immunol*. 2012;13(10):981-990. doi:10.1038/ni.2390
114. Elyaman W, Bradshaw EM, Uyttenhove C, et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. *Proc Natl Acad Sci U S A*. 2009;106(31):12885-12890. doi:10.1073/pnas.0812530106
115. Dugas B, Renaud JC, Pène J, et al. Interleukin-9 potentiates the interleukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes. *Eur J Immunol*. 1993;23(7):1687-1692. doi:10.1002/eji.1830230743
116. Matsuzawa S, Sakashita K, Kinoshita T, Ito S, Yamashita T, Koike K. IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. *J Immunol*. 2003;170(7):3461-3467. doi:10.4049/jimmunol.170.7.3461
117. Nakagome K, Imamura M, Kawahata K, et al. High expression of IL-22 suppresses antigen-induced immune responses and eosinophilic airway inflammation via an IL-10-associated mechanism. *J Immunol*. 2011;187(10):5077-5089. doi:10.4049/jimmunol.1001560
118. Johnson JR, Nishioka M, Chakir J, et al. IL-22 contributes to TGF- β 1-mediated epithelial-mesenchymal transition in asthmatic bronchial epithelial cells. *Respir Res*. 2013;14(1):118. doi:10.1186/1465-9921-14-118

119. Pennino D, Bhavsar PK, Effner R, et al. IL-22 suppresses IFN- γ -mediated lung inflammation in asthmatic patients. *J Allergy Clin Immunol.* 2013;131(2):562-570. doi:10.1016/j.jaci.2012.09.036
120. Dudakov JA, Hanash AM, van den Brink MR. Interleukin-22: immunobiology and pathology. *Annu Rev Immunol.* 2015;33:747-785. doi:10.1146/annurev-immunol-032414-112123
121. Eguiluz-Gracia I, Tay TR, Hew M, et al. Recent developments and highlights in biomarkers in allergic diseases and asthma. *Allergy.* 2018;73(12):2290-2305. doi:10.1111/all.13628
122. Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? *Nat Rev Immunol.* 2021;21(11):739-751. doi:10.1038/s41577-021-00538-7
123. Schleimer RP, Berdnikovs S. Etiology of epithelial barrier dysfunction in patients with type 2 inflammatory diseases. *J Allergy Clin Immunol.* 2017;139(6):1752-1761. doi:10.1016/j.jaci.2017.04.010
124. Desai MS, Seekatz AM, Koropatkin NM, et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. *Cell.* 2016;167(5):1339-1353.e21. doi:10.1016/j.cell.2016.10.043
125. Parrish A, Boudaud M, Kuehn A, Ollert M, Desai MS. Intestinal mucus barrier: a missing piece of the puzzle in food allergy. *Trends Mol Med.* 2022;28(1):36-50. doi:10.1016/j.molmed.2021.10.004
126. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. *Nat Genet.* 2006;38(4):441-446. doi:10.1038/ng1767
127. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. *N Engl J Med.* 2011;365(14):1315-1327. doi:10.1056/NEJMra1011040
128. Nakamura M, Kamiya K, Furuhashi A, Ikeda K, Niyonsaba F. S100A7 Co-localization and up-regulation of Filaggrin in human Sinonasal epithelial cells. *Curr Med Sci.* 2021;41(5):863-868. doi:10.1007/s11596-021-2431-1
129. Soyka MB, Wawrzyniak P, Eiwegger T, et al. Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN- γ and IL-4. *J Allergy Clin Immunol.* 2012;130(5):1087-1096.e10. doi:10.1016/j.jaci.2012.05.052
130. de Kleer IM, Kool M, de Bruijn MJ, et al. Perinatal activation of the Interleukin-33 pathway promotes type 2 immunity in the developing lung. *Immunity.* 2016;45(6):1285-1298. doi:10.1016/j.immuni.2016.10.031
131. Hiraishi Y, Yamaguchi S, Yoshizaki T, et al. IL-33, IL-25 and TSLP contribute to development of fungal-associated protease-induced innate-type airway inflammation. *Sci Rep.* 2018;8(1):18052. doi:10.1038/s41598-018-36440-x
132. Steelant B, Farré R, Wawrzyniak P, et al. Impaired barrier function in patients with house dust mite-induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression. *J Allergy Clin Immunol.* 2016;137(4):1043-1053.e5. doi:10.1016/j.jaci.2015.10.050
133. Celebi Sozener Z, Ozdel Ozturk B, Cerci P, et al. Epithelial barrier hypothesis: effect of the external exposome on the microbiome and epithelial barriers in allergic disease. *Allergy.* 2022;77(5):1418-1449. doi:10.1111/all.15240
134. Moloudizargari M, Moradkhani F, Asghari N, et al. NLRP inflammasome as a key role player in the pathogenesis of environmental toxicants. *Life Sci.* 2019 Aug;15(231):116585. doi:10.1016/j.lfs.2019.116585
135. Doyle AD, Masuda MY, Pyon GC, et al. Detergent exposure induces epithelial barrier dysfunction and eosinophilic inflammation in the esophagus. *Allergy.* 2023;78(1):192-201. doi:10.1111/all.15457
136. Haahtela T, Holgate S, Pawankar R, et al. WAO special committee on climate change and biodiversity. The biodiversity hypothesis and allergic disease: world allergy organization position statement. *World Allergy Organ J.* 2013;6(1):3. doi:10.1186/1939-4551-6-3
137. Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E. Dysbiosis and the immune system. *Nat Rev Immunol.* 2017;17(4):219-232. doi:10.1038/nri.2017.7
138. Wood LG. Asthma in the obese: a big and growing problem. *Am J Respir Crit Care Med.* 2017;195(1):4-5. doi:10.1164/rccm.201608-1582ED
139. Forno E, Han YY, Mullen J, Celedón JC. Overweight, obesity, and lung function in children and adults-a meta-analysis. *J Allergy Clin Immunol Pract.* 2018;6(2):570-581.e10. doi:10.1016/j.jaip.2017.07.010
140. Sharma V, Cowan DC. Obesity, inflammation, and severe asthma: an update. *Curr Allergy Asthma Rep.* 2021;21(12):46. doi:10.1007/s11882-021-01024-9
141. Sunadome H, Matsumoto H, Izuhara Y, et al. Correlation between eosinophil count, its genetic background and body mass index: the Nagahama study. *Allergol Int.* 2020;69(1):46-52. doi:10.1016/j.alit.2019.05.012
142. Zheng H, Wu D, Wu X, et al. Leptin promotes allergic airway inflammation through targeting the unfolded protein response pathway. *Sci Rep.* 2018;8(1):8905. doi:10.1038/s41598-018-27278-4
143. Russo S, Kwiatkowski M, Govorukhina N, Bischoff R, Melgert BN. Meta-inflammation and metabolic reprogramming of macrophages in diabetes and obesity: the importance of metabolites. *Front Immunol.* 2021;5(12):746151. doi:10.3389/fimmu.2021.746151
144. Michalovich D, Rodriguez-Perez N, Smolinska S, et al. Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients. *Nat Commun.* 2019;10(1):5711. doi:10.1038/s41467-019-13751-9

145. Raybould HE. Gut microbiota, epithelial function and derangements in obesity. *J Physiol.* 2012;590(3):441-446. doi:10.1113/jphysiol.2011.222133
146. Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. *Lancet Diabetes Endocrinol.* 2015;3(3):207-215. doi:10.1016/S2213-8587(14)70134-2
147. Smolinska S, Jutel M, Cramer R, O'Mahony L. Histamine and gut mucosal immune regulation. *Allergy.* 2014;69(3):273-281. doi:10.1111/all.12330
148. Barcik W, Pugin B, Brescò MS, et al. Bacterial secretion of histamine within the gut influences immune responses within the lung. *Allergy.* 2019;74(5):899-909. doi:10.1111/all.13709
149. Jutel M, Watanabe T, Klunker S, et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. *Nature.* 2001;413(6854):420-425. doi:10.1038/35096564
150. Forde B, Yao L, Shaha R, Murphy S, Lunjani N, O'Mahony L. Immunomodulation by foods and microbes: unravelling the molecular tango. *Allergy.* 2022;77(12):3513-3526. doi:10.1111/all.15455
151. Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. *Allergy.* 2013;68(10):1219-1232. doi:10.1111/all.12260
152. Doña I, Barrionuevo E, Salas M, et al. NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organs. *Sci Rep.* 2018;8(1):16710. doi:10.1038/s41598-018-34668-1
153. Doña I, Jurado-Escobar R, Perkins JR, et al. Eicosanoid mediator profiles in different phenotypes of nonsteroidal anti-inflammatory drug-induced urticaria. *Allergy.* 2019;74(6):1135-1144. doi:10.1111/all.13725
154. Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)-a EAACI position paper. *Allergy.* 2019;74(1):28-39. doi:10.1111/all.13599
155. Taniguchi M, Mitsui C, Hayashi H, et al. Aspirin-exacerbated respiratory disease (AERD): current understanding of AERD. *Allergol Int.* 2019;68(3):289-295. doi:10.1016/j.alit.2019.05.001
156. White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. *N Engl J Med.* 2018;379(11):1060-1070. doi:10.1056/NEJMra1712125
157. Hybar H, Saki N, Maleknia M, Moghaddasi M, Bordbar A, Naghavi M. Aspirin exacerbated respiratory disease (AERD): molecular and cellular diagnostic & prognostic approaches. *Mol Biol Rep.* 2021;48(3):2703-2711. doi:10.1007/s11033-021-06240-0
158. Lyly A, Laidlaw TM, Lundberg M. Pathomechanisms of AERD-recent advances. *Front Allergy.* 2021;2:734733. doi:10.3389/falgy.2021.734733
159. Kohanski MA, Cohen NA, Barrett NA. Epithelial dysregulation in chronic rhinosinusitis with nasal polyposis (CRSwNP) and aspirin-exacerbated respiratory disease (AERD). *J Allergy Clin Immunol.* 2021;148(5):1161-1164. doi:10.1016/j.jaci.2021.07.034
160. Zhang T, Che D, Liu R, et al. Typical antimicrobials induce mast cell degranulation and anaphylactoid reactions via MRGPRX2 and its murine homologue MRGPRB2. *Eur J Immunol.* 2017;47(11):1949-1958. doi:10.1002/eji.201746951
161. Fujisawa D, Kashiwakura J, Kita H, et al. Expression of mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. *J Allergy Clin Immunol.* 2014;134(3):622-633.e9. doi:10.1016/j.jaci.2014.05.004
162. McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. *Nature.* 2015;519(7542):237-241. doi:10.1038/nature14022
163. da Silva EZ, Jamur MC, Oliver C. Mast cell function: a new vision of an old cell. *J Histochem Cytochem.* 2014;62(10):698-738. doi:10.1369/0022155414545334
164. Prussin C, Metcalfe DD. 4. IgE, mast cells, basophils, and eosinophils. *J Allergy Clin Immunol.* 2003;111(2 Suppl):S486-S494. doi:10.1067/mai.2003.120
165. Jutel M, Mosnaim GS, Bernstein JA, et al. The one health approach for allergic diseases and asthma. *Allergy.* 2023;78(7):1777-1793. doi:10.1111/all.15755

The online version of the article has been corrected.

We apologize for this error.